Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.55 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25246952 | 0.92 | CRBN (0.61) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL30930681 | 0.78 | CRBN (0.56) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| SCHEMBL27283351 | 0.78 | CRBN (0.56) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| SCHEMBL30930629 | 0.78 | CRBN (0.56) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL26185854 | 0.78 | CRBN (0.61) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL29761409 | 0.78 | CRBN (0.61) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| SCHEMBL25252129 | 0.78 | CRBN (0.60) | CRBNIKZF2CSNK1A1IKZF1 | |
| Trifluoroacetic Acid SCHEMBL31635891 | 0.77 | IKZF2 (0.69) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| SCHEMBL30415274 | 0.77 | CRBN (0.57) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 | |
| SCHEMBL25242812 | 0.77 | CRBN (0.57) | CRBNIKZF2CSNK1A1GSPT1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | CRBN 3187/4885IKZF2 3603/4885CSNK1A1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.